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Abstract
In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding sero-
tonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour
set for receptor mRNA overexpression using functional genomic mRNA (FGmRNA) profiling, and we analysed protein expres-
sion and location of 5-HTR1B, 5-HTR2B, DRD1, and DRD2 with immunohistochemistry in different tumour types. With
FGmRNA profiling 11,756 samples representing 43 tumour types were compared to 3,520 normal tissue samples to analyse
receptor overexpression. 5-HTR2B overexpression was present in many tumour types, most frequently in uveal melanomas
(56%). Receptor overexpression in rare cancers included 5-HTR1B in nasopharyngeal carcinoma (17%), DRD1 in ependymoma
(30%) and synovial sarcoma (21%), and DRD2 in astrocytoma (13%). Immunohistochemistry demonstrated high 5-HTR2B
protein expression on melanoma and gastro-intestinal stromal tumour cells and endothelial cells of colon, ovarian, breast, renal
and pancreatic tumours. 5-HTR1B expression was predominantly low. High DRD2 protein expression on tumour cells was
observed in 48% of pheochromocytomas, and DRD1 expression ranged from 14% in melanoma to 57% in renal cell carcinoma.
In conclusion, 5-HTR1B, 5-HTR2B, DRD1, and DRD2 show mRNA overexpression in a broad spectrum of common and rare
cancers. 5-HTR2B protein is frequently highly expressed in human cancers, especially on endothelial cells. These findings
support further investigation of especially 5HTR2B as a potential treatment target.
Keywords Serotonin receptor 1B . Serotonin receptor 2B .Dopamine receptorD2 .Dopamine receptorD1 .Neovascularization .
Neoplasms
Introduction
Serotonin and dopamine are biogenic amines, which are pro-
duced in the central nervous system and gastrointestinal tract.
Throughout the body, they are transported by platelets.
Serotonin and dopamine play a role in vascular tone, gastro-
intestinal motility, limb movement control and other physio-
logical processes [1, 2]. Preclinical studies discovered that
serotonin and dopamine also influence tumour angiogenesis
and tumour growth [3–10].
Angiogenesis is one of the hallmarks of cancer. It is a
prerequisite for tumour growth as it secures oxygen and nutri-
ent supply and removal of break-down products from the tu-
mour microenvironment [11]. Serotonin stimulates tumour
angiogenesis via activation of serotonin receptor 1B (5-
HTR1B) and serotonin receptor 2B (5-HTR2B) [3–5].
Serotonin can also directly stimulate tumour cell proliferation
via various serotonin receptors on tumour cells [10], whereas
depletion of serotonin in mice with murine melanoma and
lung tumours resulted in slower growth compared with mice
having normal serotonin concentrations [5]. Research demon-
strated that dopamine inhibits angiogenesis and thereby
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tumour growth in animal models of colon cancer, ovarian
cancer, and breast cancer via activation of dopamine re-
ceptor D2 (DRD2) [6, 7]. On the opposite, it was shown
that the DRD2 pathway is activated in human pancreatic
cancer and that growth of pancreatic cancer xenografts
was inhibited by DRD2 antagonists in mice [12].
Contradictory results have also been published for dopa-
mine receptor D1 (DRD1), as both inhibition as well as
stimulation of tumour growth has been reported upon re-
ceptor activation in animal models of ovarian cancer and
breast cancer [6, 8, 9].
Serotonin and dopamine receptor agonists and antago-
nists are prescribed for the treatment of Parkinson’s dis-
ease, psychosis, nausea, and migraine [1, 13, 14], but
have not been explored for an anti-tumour effect in cancer
patients. Information regarding serotonin and dopamine
receptor expression in human cancers is limited.
Therefore, we screened for 5-HTR1B, 5-HTR2B, DRD1,
and DRD2 mRNA overexpression in a large dataset with
common and rare tumour types using functional genomic
mRNA (FGmRNA) profiling and we determined protein
expression and localization of the serotonin and dopamine




RNA microarray expression data of 11,756 human tumour
samples were collected from Gene Expression Omnibus
(GEO), a large publicly available data set [15]. From these
expression data, FGmRNA profiles were created. Detailed
information about FGmRNA profiling was described previ-
ously [16]. In short, principal component analysis is used to
identify major regulators of the mRNA transcriptome. These
so-called transcriptional components are used to correct the
mRNA expression data for non-genetic differences, such as
physiological and metabolic factors. The expression signal
that remains after correction represents variance in mRNA
expression due to genetic alterations. This is called the
FGmRNA profile.
To determine a threshold for overexpression, FGmRNA
profiling of 3,520 normal human tissue samples was per-
formed, and the 97.5th percentile for 5-HTR1B, 5-
HTR2B, DRD1 and DRD2 was ca lcula ted (see
Supplementary Table 1 for an overview of non-cancer
samples). For all tumour types, the percentage of samples
with overexpression was calculated for each of the four
receptors. Only tumour types with >10 samples available
were used for this calculation.
Immunohistochemistry
Patient Material
Selection of tumour types for immunohistochemistry was
based on results from preclinical studies (colon cancer, ovar-
ian cancer, breast cancer, pancreatic cancer, melanoma) [5–8,
12] or tumour characteristics (high vascularity for renal cell
carcinoma, dopamine production for pheochromocytoma, and
serotonin-induced proliferation of precursor cells for gastroin-
testinal stromal tumours (GIST)) [17, 18].
Formalin-fixed paraffin-embedded primary tumour tis-
sues of colon cancer (n = 12), ovarian cancer (n = 12),
breast cancer (n = 12), renal cell carcinoma (n = 14), and
pancreatic cancer (n = 12) were used. A minimum of 12
tumours were selected per tumour type, because if 0/12
tumour samples show expression, the chance that it is
relevant in >10% of patients is low. Furthermore, 3 tissue
microarrays (TMA) were used, namely a melanoma TMA
containing 36 tumour samples, a pheochromocytoma
TMA containing 63 tumour samples, and a GIST TMA
containing 76 tumour samples. The TMAs contained 3
cores with a diameter of 0.6 mm per patient.
Tissue samples used in this study were archival material.
According to the Dutch Medical Research Involving Human
Subjects act, no approval of the Institutional Review Board
was required.
Immunohistochemical Procedure and Analysis
Formalin-fixed, 4 μm thick paraffin-embedded sections and
TMAs were deparaffinized and rehydrated. Antigen retrieval
was performed using heated citrate buffer (pH 6.0) for 5-
HTR1B, 5-HTR2B, DRD1, and DRD2 or tris/EDTA buffer
(pH 9.0) for CD31 for 15min. For DRD2, slides were blocked
with phosphate-buffered saline (PBS; pH 7,4) plus 0.1%
Tween-20 for 20 min at room temperature. Endogen peroxi-
dase was blocked in all slides with 1% H2O2 in PBS for
30 min at room temperature. For 5-HTR1B, additional
avidin/biotin (avidin/biotin blocking kit (SP-2001); Vector
Labora tor ies , Brunschwig Chemie , Amsterdam,
The Netherlands) and human serum blocks were performed.
The sections were incubated with the primary antibody for 1 h
at room temperature for 5-HTR2B, DRD1, and CD31 or over-
night at 4 °C for 5-HTR1B and DRD2. Primary antibodies
used were mouse monoclonal 5-HTR1B 1:100 (clone
499,325; MAB5858, R&D systems, Abingdon, United
Kingdom), mouse monoclonal 5-HTR2B 1:1000 (clone H-
11; sc-376,834, Santa Cruz Biotechnology, Bio-Connect,
Huissen, The Netherlands), mouse monoclonal DRD2 1:100
(clone B-10, sc-5303, Santa Cruz Biotechnology), rat mono-
clonal DRD1 1:75 (clone 1–1-F11 s.E6; D2944, Sigma
Aldrich, Zwijndrecht, The Netherlands), and mouse
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monoclonal CD31 1:50 (clone JC70A; IR610, DAKO,
Glostrup, Denmark). Subsequently, tissue sections were incu-
bated with secondary antibodies (1:100 dilution or in case of
5-HTR1B a 1:300 dilution; all from DAKO). Between steps,
slides were washed with PBS or in case of DRD2 with PBS
plus 0.1% Tween-20. Staining was visualized using 3,3′-di-
aminobenzidine (DAB) and hematoxylin for counterstaining.
Positive and negative controls (including immunoglobulin
class-matched control sera) were included for each staining.
Colon, testis, and prostate tissue served to validate the
stainings as positive and negative controls. In addition stan-
dard hematoxylin & eosin (H&E) stainings were performed to
evaluate tissue morphology.
Analysis of Immunohistochemistry
After immunohistochemical staining, slides were digitally
scanned using the NanoZoomer (Hamamatsu Photonics,
Shizuoka, Japan) and were scored using accompanied
NanoZoomer Digital Pathology (NDP) software. All slides
were scored by two independent investigators (M.P. and
C.M. or H.H.) and compared to assure a minimal inter-
observer difference. As an extra control, random slides were
also evaluated by a pathologist (H.H.).
Tissue morphology was evaluated using H&E-stained
slides. Staining intensity of the tumour cells and percent-
age of positive tumour cells was scored. Staining intensity
of tumour cells was scored as negative (0), low (1), mod-
erate (2), or high (3). The percentage of positive tumour
cells was scored as no positive cells (0), 1–4% positive
cells (1), 5–24% positive cells (2), 25–49% positive cells
(3), 50–74% positive cells (4), and 75–100% positive
cells (5). Receptor expression was scored using an immu-
noreactive score (IRS) to account for the heterogeneous
staining in the section slides [19]. The IRS was defined by
multiplying the staining intensity (category 0–3) with the
percentage of positive tumour cells (category 0–5), creat-
ing a range from 0 to 15. Receptor expression was con-
sidered negative if IRS was 0, low if the IRS was 1 to 5,
and high if the IRS was 6 to 15. For TMAs, at least two
evaluable cores had to be present per tumour in order to
consider it a representative score.
Receptor expression on tumour-associated blood ves-
sels was only assessed on the whole tissue sections, as
blood vessels were only in limited numbers or not at all
present in the TMA samples due to their small diameter.
Serotonin and dopamine receptor expression was scored
by staining intensity (ranging from 0 to 3). Receptor
expression was considered negative if intensity was 0,
low if intensity was 1, and high if intensity was 2 or 3,
CD31 staining was performed to confirm localization of
tumour vessels.
Results
Overexpression of Serotonin and Dopamine
Receptors Analysed with FGmRNA Profiling
For the frequency of overexpression of serotonin and dopa-
mine receptors per tumour type, see Table 1.
5-HTR1B was overexpressed in a low percentage of tu-
mour samples per tumour type. The highest percentage was
found in nasopharyngeal carcinoma: in 7 of 42 (17%)
samples.
Of the four receptors, 5-HTR2B was most frequently
overexpressed, especially in uveal melanomas (59 of 106
(56%) samples). Also in certain brain tumours and sarcomas,
and in hepatocellular carcinoma and non-small cell lung can-
cer, a relatively high proportion of tumour samples showed
overexpression of 5-HTR2B: 6 out of 24 astrocytomas (25%),
15 out of 76 liposarcomas (20%), 4 out of 26 osteosarcomas
(15%), 71 out of 346 hepatocellular carcinomas (20%) and 16
out of 103 small cell lung cancers (16%).
Overexpression of DRD1 was most frequently found in
ependymoma and synovial sarcoma with 46 out of 156
(30%) respectively 7 out of 34 (21%) of the samples.
DRD2 was most frequently overexpressed in adrenal neu-
roblastoma (24 out of 96 (25%) samples) and astrocytoma (3
out of 24 (13%) samples).
Serotonin and Dopamine Receptor Expression
Analysed with Immunohistochemistry
Tumour cells predominantly had low or absent 5-HTR1B ex-
pression, except for 10 out of 12 colon cancers and 4 out of 12
ovarian cancers showing high 5-HTR1B expression. 5-
HTR2B was highly expressed on tumour cells of all melano-
mas and all but 2 GIST. Pheochromocytomas showed either
absent or very high expression of 5-HTR2B on tumour cells.
In some pheochromocytomas (n = 12), also small foci of
strongly positive tumour cells were observed within a
field of negative tumour cells. DRD1 was highly
expressed on tumour cells of approximately 50% of colon
cancers, ovarian cancers, breast cancers, renal cell carci-
nomas and GIST samples. For melanoma and pheochro-
mocytoma, this was the case in less than 25% of samples.
High DRD2 expression by tumour cells was most fre-
quently observed in pheochromocytomas (30 out of 63
samples), ovarian cancer (6 out of 12 samples) and pan-
creatic cancer (6 out of 12 samples) (Fig. 1).
5-HTR1B expression was predominantly low or absent on
endothelial cells, except for 6 out of 12 colon cancers and 4
out of 12 ovarian cancers. 5-HTR2B, on the other hand, was
highly expressed on endothelial cells of all tumour types in-
vestigated (colon, ovarian, breast, renal, and pancreatic can-
cer). Expression of DRD1 on endothelial cells varied per
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Table 1 Overexpression of serotonin and dopamine receptors in different tumour types determined with functional genomic mRNA analysis
Percentage overexpression (%)
Tumor type (N) 5-HTR1B 5-HTR2B DRD1 DRD2
Breast cancer
ER-/Her2+ (455) 6.6 3.5 2.0 1.1
ER+/Her2- (1,678) 3.4 4.5 1.0 0.6
ER+/Her2+ (506) 3.8 4.5 1.4 0.6
TNBC (737) 7.3 3.5 0.7 1.2
CNS malignancies
Anaplastic astrocytoma (36) 5.6 8.3 2.8 0.0
Anaplastic oligodendroglioma (26) 3.8 0.0 0.0 0.0
Astrocytoma (24) 4.2 25.0 4.2 12.5
Ependymoma (156) 1.3 0.0 29.5 0.6
Glioblastoma (389) 1.8 2.1 1.3 0.3
Medulloblastoma (148) 2.7 4.1 0.7 6.8
Meningioma (122) 3.8 7.6 0.0 2.5
Oligodendroglioma (23) 4.3 13.0 4.3 4.3
Pilocytic astrocytoma (135) 0.7 3.0 0.0 0.0
Endocrine malignancies
Adrenal neuroblastoma (96) 4.2 5.2 1.0 25.0
Adrenocortical carcinoma (20) 0.0 10.0 0.0 0.0
Anaplastic thyroid carcinoma (21) 0.0 14.3 0.0 0.0
Papillary thyroid carcinoma (51) 2.0 7.8 0.0 0.0
Gastrointestinal malignancies
Colorectal cancer (2,710) 1.3 4.3 0.9 3.7
Esophageal adenocarcinoma (41) 4.9 14.6 7.3 0.0
Esophageal squamous cell carcinoma (56) 0.0 3.6 0.0 0.0
Gastric cancer (332) 3.9 12.0 7.8 0.6
Hepatocellular carcinoma (364) 3.3 19.5 6.0 0.0
Pancreatic cancer (81) 0.0 8.6 1.2 0.0
Genitourinary malignancies
Bladder cancer (39) 5.1 7.7 7.7 2.6
Chromophobe renal cancer (37) 0.0 0.0 0.0 2.7
Clear cell renal cancer (225) 5.8 7.6 0.9 1.8
Papillary renal cancer (37) 0.0 0.0 0.0 0.0
Prostate cancer (308) 3.6 5.2 0.6 1.9
Gynaecological malignancies
Cervical cancer (62) 1.6 6.5 0.0 3.2
Ovarian cancer (187) 0.5 3.7 0.5 0.0
Head and neck cancer
HNSCC (344) 4.9 0.6 2.0 1.2
Nasopharyngeal carcinoma (42) 16.7 11.9 0.0 2.4
Lung cancer
Adenocarcinoma (1,019) 1.6 7.8 2.7 0.5
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tumour type. In breast cancer, DRD1 was highly
expressed on endothelial cells of 7 out of 12 samples.
For the other tumour types, high expression of DRD1 on
endothelial cells was only observed in 4 out of 14 renal
cell carcinomas and 1 pancreatic cancer sample. DRD2
expression was low or absent on endothelial cells
(Fig. 2).
For representative images of serotonin and dopamine re-
ceptor staining on ovarian cancer cells and tumour blood ves-
sels, see Fig. 3a and b.
Fig. 1 a Serotonin receptor 1B
(5-HTR1B), b serotonin receptor
2B (5-HTR2B), c dopamine
receptor D1 (DRD1), d and
dopamine receptor D2 (DRD2)
expression on tumour cells of co-
lon cancer (CC) (n = 12), ovarian
cancer (OC) (n = 12), breast can-
cer (BC) (n = 12), renal cell car-
cinoma (RCC) (n = 14), pancreat-
ic cancer (PC) (n = 12), melano-
ma (M) (n = 36), pheochromocy-
toma (PCC) (n = 63) and gastro-
intestinal stromal tumours (GIST)
(n = 76) as analysed with immu-
nohistochemistry.
Immunoreactive score (IRS) was
used to classify receptor expres-
sion on tumour cells in three cat-
egories: negative (in white), low




Tumor type (N) 5-HTR1B 5-HTR2B DRD1 DRD2
Squamous cell carcinoma (405) 0.2 2.7 1.5 0.5
Small cell lung cancer (103) 1.0 15.5 4.9 8.7
Melanoma
Cutaneous (398) 3.8 9.0 0.0 1.3
Uveal (106) 2.8 55.7 2.8 0.9
Sarcoma
Ewing’s sarcoma (26) 3.8 0.0 0.0 3.8
Leiomyosarcoma (60) 1.7 6.7 5.0 5.0
Liposarcoma (76) 3.9 19.7 1.3 1.3
Osteosarcoma (26) 0.0 15.4 0.0 0.0
Primitive neuroectodermal tumor (22) 4.5 0.0 0.0 4.5
Synovial sarcoma (34) 0.0 0.0 20.6 0.0
Undifferentiated sarcoma (95) 1.1 9.5 1.1 0.0
N; number, 5-HTR1B; serotonin receptor 1B, 5-HTR2B; serotonin receptor 2B, DRD1; dopamine receptor D1, DRD2; dopamine receptor D2, ER;
estrogen receptor, Her2; human epidermal growth factor receptor 2, TNBC: triple negative breast cancer, CNS; central nervous system, HNSCC; head
and neck squamous cell carcinoma
Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers 1543
Discussion
To our knowledge, this is the first study evaluating 5-HTR1B,
5-HTR2B, DRD1, and DRD2 (over)expression in a broad
range of tumour types with both FGmRNA profiling and im-
munohistochemistry. We found that 5-HTR2B is more fre-
quently overexpressed compared to 5-HTR1B, DRD1, and
DRD2. All four receptors, however, are expressed across tu-
mour types including rare cancers. 5-HTR2B is highly
expressed on tumour cells in all melanomas and on tumour
endothelial cells of colon, ovarian, breast, renal, and pancre-
atic cancer samples.
One of the great advantages of FGmRNA is that it enabled
us to screen overexpression of serotonin and dopamine recep-
tors in a large number of samples, leading to interesting find-
ings in rare cancers like brain tumours and sarcomas.
FGmRNA profiling identified mRNA overexpression based
on a strictly chosen cut-off level, being receptor expression
higher than the 97.5th percentile of expression in normal tis-
sue (16). This may have led to the relatively low overexpres-
sion percentages found with FGmRNA profiling compared
with the number of samples with high expression found with
immunohistochemistry.
FGmRNA profiling and immunohistochemistry both dem-
onstrated high 5-HTR2B expression in (uveal) melanoma.
Two in vitro studies evaluated the effect of serotonin on mel-
anoma growth with opposite results. Serotonin inhibited pro-
liferation of 5-HTR2B expressing human melanoma cell line
IPC298 but it did not affect B16F0 murine melanoma cell
proliferation, in which however, receptor expression was not
assessed [5, 20]. On the other hand, mice with serotonin de-
pletion due to knockout of a serotonin transporter had smaller
B16F0 murine melanomas than mice with a functional sero-
tonin transporter and thus unaffected serotonin concentrations
in blood [5].
5-HTR2B was highly expressed on endothelial cells of five
tumour types evaluated using immunohistochemistry (colon
cancer, ovarian cancer, breast cancer, renal cell carcinoma,
and pancreatic cancer). This was in concordance with studies
from a research group from Malmö, Sweden, which demon-
strated 5-HTR2B protein expression by endothelial cells in 29
ovarian cancer and 102 breast cancer samples [21, 22]. In
preclinical studies, the effect of 5-HTR2B antagonists on an-
giogenesis was evaluated: phosphorylation of serotonin-
induced endothelial nitric oxide synthase (eNOS) was blocked
in human umbilical vein endothelial cells (HUVEC) and in a
murine lung cancer model, and was associated with decreased
tumour microvessel density [5].
Preclinical research demonstrated that dopamine inhibits
tumour angiogenesis via activation of DRD2. To our knowl-
edge, this is the first study evaluating DRD2 expression on
vasculature of human tumours. Previous studies demonstrated
DRD2 protein expression on vessels of mouse ears and
HUVEC [6]. In our study however, we observed low or absent
DRD2 protein expression on tumour-associated endothelial
cells. On tumour cells of 30/63 pheochromocytomas, DRD2
Fig. 2 a Serotonin receptor 1B
(5-HTR1B), b serotonin receptor
2B (5-HTR2B), c dopamine
receptor D1 (DRD1), d and
dopamine receptor D2 (DRD2)
expression on endothelial cells of
colon cancer (CC) (n = 12), ovar-
ian cancer (OC) (n = 12), breast
cancer (BC) (n = 12), renal cell
carcinoma (RCC) (n = 14), and
pancreatic cancer (PC) (n = 12) as
analysed with immunohisto-
chemistry. Receptor expression
was classified by staining intensi-
ty. Receptor expression was con-
sidered negative if intensity was 0
(white), low if intensity was 1 (in
light grey), and high if intensity
was 2 or 3 (in dark grey)
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protein was highly expressed. This was in concordance with
smaller studies in 10 respectively 39 pheochromocytomas [23,
24]. Interestingly, a phase I study with the DRD2 antagonist
ONC201, demonstrated some clinical benefit in five endome-
trial and prostate cancer patients from a group of 27 advanced
cancer patients [25]. However, a phase II study with ONC201
in 17 recurrent glioblastoma patients was closed after interim
analysis since the target of a six month progression-free sur-
vival in 30% of patients was not reached [26]. In both studies,
DRD2 expression was not evaluated. If the patient population
could have been enriched based on target expression remains
therefore unclear. Pituitary adenoma is a tumour type known
to express DRD2, and the DRD2 agonist bromocriptine is
already part of the standard treatment regimen in prolactin-
producing adenomas [1, 27]. Dependent on tumour type and
DRD2 expression on tumour cells, treatment with a DRD2
agonist or antagonist may have anti-tumour activity. For anti-
angiogenic treatment however, the significance of DRD2 ag-
onists seems limited based on our results regarding expression
of this receptor on tumour-associated blood vessels.
In conclusion, serotonin and dopamine receptors are differen-
tially (over)expressed in various tumour types by tumour and
Fig. 3 a Representative images of low and high expression of serotonin
receptor 1B (5-HTR1B), serotonin receptor 2B (5-HTR2B), dopamine
receptor D1 (DRD1), and dopamine receptor D2 (DRD2) by tumour cells
in ovarian cancer (10x magnification). b Representative images of nega-
tive and positive (low or high) expression of serotonin receptor 1B (5-
HTR1B), serotonin receptor 2B (5-HTR2B), dopamine receptor D1
(DRD1), and dopamine receptor D2 (DRD2) on blood vessels in ovarian
cancer (40x magnification). Arrowheads indicate blood vessels that ex-
press the receptor of interest
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endothelial cells. Of these, 5-HTR2B is expressedmost frequent-
ly. This study demonstrates that selection of patients with tu-
mours of different backgrounds but with similar receptor expres-
sion profiles is possible. This could offer interesting future pos-
sibilities for basket studies. Basket studies include different tu-
mour types and select patients with the same tumour character-
istic for targeted treatment [28]. This allows to study new treat-
ment modalities in rare tumours, such as brain tumours and
sarcomas, for which there are currently limited treatment options.
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